Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03292185
Other study ID # NN9068-4139
Secondary ID U1111-1155-0990
Status Completed
Phase Phase 1
First received
Last updated
Start date September 29, 2017
Est. completion date January 2, 2018

Study information

Verified date November 2019
Source Novo Nordisk A/S
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main purpose of the trial is to compare the bioavailability (extent of drug absorption into the circulation) of insulin degludec and liraglutide as part of a combination product insulin degludec/liraglutide compared to the corresponding doses of single, separate injections of insulin degludec and liraglutide. Participants will receive all three test substances. The order of trial administration will be allocated by chance. During the trial period, serials of blood samples will be collected from the participants at three dosing periods, in order to determine the concentration of insulin degludec and liraglutide. The total volume of blood taken throughout the whole trial period will be less than 400 mL. Participants will be asked to stay on daytime and overnight in the trial sites on some predefined days. For other outpatient days, participants need to attend the trial site as required for drug administration or required assessments.


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date January 2, 2018
Est. primary completion date January 2, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion criteria:

- Male and female Chinese subjects, who are considered to be generally healthy, based on assessment of medical history, physical examination, and clinical laboratory data, as judged by the investigator

- Age between 18 to 45 years (both inclusive) at the time of signing informed consent

- Body mass index (BMI) between 19.0 and 24.0 kg/sqm (both inclusive)

- Body weight at least 50.0 kg

- Fasting plasma glucose less than 6.1 mmol/L (110 mg/dL)

Exclusion criteria:

- Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential not using an adequate contraceptive methods throughout the trial including follow-up period. Adequate contraceptive measures are sterilisation, intrauterine device (IUD), oral contraceptives or barrier methods

- Donation of any blood or plasma in the past month or in excess of 400 mL within the 90 days preceding screening or surgery or trauma with more than 400 mL blood loss within the 90 days preceding screening

- History or presence of cancer, or any clinically significant cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrine (incl. diabetes and recurrent hypoglycaemia), haematological, dermatological, venereal, neurological, psychiatric diseases or other major disorders that might have impact on the trial result, as judged by the investigator

- Use of any prescription or non-prescription medication, except for paracetamol, acetylsalicylic acid, contraceptives and vitamins (mega-dose vitamin therapy not allowed, dose judged by the investigator) within 2 weeks prior to screening

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
insulin degludec/liraglutide
Insulin Degludec/Liraglutide combination product with 0.61 mg Liraglutide and 17 U Insulin Degludec, single dose administration under the skin in the thigh.
insulin degludec
17 U Insulin Degludec, single dose administration under the skin in the thigh.
liraglutide
0.6 mg Liraglutide, single dose administration under the skin in the thigh

Locations

Country Name City State
China Novo Nordisk Investigational Site Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Novo Nordisk A/S

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Area under the serum insulin degludec concentration time curve Calculated based on insulin degludec concentration in serum From 0 to last quantifiable observation after single dose of insulin degludec/liraglutide and insulin degludec, assessments from 0 hours to 120 hours
Primary Area under the plasma liraglutide concentration time curve Calculated based on liraglutide concentration in plasma from 0 to last quantifiable observation after single dose of insulin degludec/liraglutide and liraglutide, assessments from 0 hours to 72 hours
Secondary Area under the serum insulin degludec concentration time curve from 0 to infinity after single dose Calculated based on insulin degludec measured in serum 0 hours to 120 hours
Secondary Maximum observed serum insulin degludec concentration Calculated based on insulin degludec measured in serum 0 hours to 120 hours
Secondary Time to maximum serum insulin degludec concentration Calculated based on insulin degludec measured in serum 0 hours to 120 hours
Secondary Terminal elimination half-life for insulin degludec Calculated based on insulin degludec measured in serum 0 hours to 120 hours
Secondary Area under the plasma liraglutide concentration time curve from 0 to infinity after single dose Calculated based on liraglutide measured in plasma 0 hours to 72 hours
Secondary Maximum observed plasma liraglutide concentration Calculated based on liraglutide measured in plasma 0 hours to 72 hours
Secondary Time to maximum plasma liraglutide concentration Calculated based on liraglutide measured in plasma 0 hours to 72 hours
Secondary Terminal elimination half-life of liraglutide Calculated based on liraglutide measured in plasma 0 hours to 72 hours
Secondary Number of treatment emergent adverse events Count Visit 2 (Day 1, randomisation), Visit 5 (7-14 days after last dosing visit)
Secondary Number of treatment emergent hypoglycaemic episodes Count Visit 2 (Day 1, randomisation), Visit 5 (7-14 days after last dosing visit)
Secondary Local tolerability at the injection site Count Visit 2 (Day 1, randomisation), Visit 5 (7-14 days after last dosing visit)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05666479 - CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
Completed NCT05647083 - The Effect of Massage on Diabetic Parameters N/A
Active, not recruiting NCT05661799 - Persistence of Physical Activity in People With Type 2 Diabetes Over Time. N/A
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Completed NCT02836704 - Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose) Phase 4
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Completed NCT04562714 - Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy N/A
Completed NCT02009488 - Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT05896319 - Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2 N/A
Recruiting NCT05598203 - Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes N/A
Completed NCT05046873 - A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People Phase 1
Terminated NCT04090242 - Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes N/A
Completed NCT04030091 - Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus Phase 4
Completed NCT03620357 - Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D) N/A
Completed NCT03604224 - A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT03620890 - Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy Phase 4
Withdrawn NCT05473286 - A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Completed NCT04531631 - Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes Phase 2